News
CVS
55.30
+0.27%
0.15
CVS Health Corporation Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now
CVS Health Corporation (NYSE:CVS) fell 18% after its first-quarter report. Earnings per share fell 33% below analyst forecasts. The stock is now down 18% to US$55.15. The analysts seem to have become more bearish following the company's results. CVS Health's revenue growth is expected to slow down compared to the wider industry. The consensus price target for the company has fallen 15% following the report.
Simply Wall St · 16h ago
I'm Buying The Dip With Up To 7% Yield
Enterprise Products Partners offers a 7% yield and has strong fundamentals, including a well-covered distribution and positive outlook. CVS Health has a 5% yield but has experienced a dip in price after reporting first quarter earnings. The healthcare giant's stock has been punished for higher medical utilization, but its business is growing.
Seeking Alpha · 17h ago
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of CVS Health Corporation (CVS) on Behalf of Investors
Glancy Prongay & Murray LLP has commenced an investigation on behalf of CVS Health Corporation investors concerning the Company’s possible violations of the federal securities laws. On May 1, 2024, CVS released its first quarter 2024 financial results. The Company lowered its forecast for cash flow from operations by $1.5 billion and its stock price fell 16.8%.
Barchart · 19h ago
SPY ETF Update, 5/3/2024  
SPY is a Moderate Buy. The Street’s average price target of $580.53 implies an upside of more than 15%. The S&P 500 is down 1.01% in the past 5 days but has risen about 25% over the past year. SPY's five holdings have the highest upside potential.
TipRanks · 22h ago
INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of CVS Health Corporation (CVS) on Behalf of Investors
Law Offices of Howard G. Smith announces an investigation on behalf of CVS Health Corporation investors. On May 1, 2024, CVS released its first quarter 2024 financial results. The Company cited increased medical costs in its Medicare insurance business as the cause of the lowered guidance. CVS’s stock price fell $11.40, or 16.8%, to close at $53.31 per share.
Barchart · 1d ago
CVS Health Is Maintained at Buy by B of A Securities
Dow Jones · 1d ago
The Law Offices of Frank R. Cruz Announces Investigation of CVS Health Corporation (CVS) on Behalf of Investors
The Law Offices of Frank R. Cruz announces an investigation of CVS Health Corporation. On May 1, 2024, CVS released its first quarter 2024 financial results. The Company lowered its forecast for cash flow from operations by $1.5 billion. CVS’s stock price fell $11.40, or 16.8%, to close at $53.31 per share.
Barchart · 1d ago
B of A Securities Maintains Buy on CVS Health, Lowers Price Target to $77
Benzinga · 1d ago
CVS Health Is Maintained at Buy by Goldman Sachs
Dow Jones · 1d ago
CVS Health Price Target Cut to $74.00/Share From $85.00 by Goldman Sachs
Dow Jones · 1d ago
Goldman Sachs Maintains Buy on CVS Health, Lowers Price Target to $74
Benzinga · 1d ago
CVS Health Is Maintained at Equal-Weight by Barclays
Dow Jones · 1d ago
CVS Health Price Target Cut to $63.00/Share From $78.00 by Barclays
Dow Jones · 1d ago
CVS Health Stock: Free-Falling After Major Earnings Miss, Blame Game Begins
CVS Health Corporation missed revenue and earnings expectations for Q1 2024, leading to a 17% drop in stock value. Medicare Advantage utilization pressures and rising healthcare costs are major contributors to the disappointing performance. CVS stock has fallen to a five-year low of $57 per share. The company is facing increasing competition in the Medicare Advantage market.
Seeking Alpha · 1d ago
Barclays Maintains Equal-Weight on CVS Health, Lowers Price Target to $63
Benzinga · 1d ago
CVS Health Price Target Cut to $60.00/Share From $85.00 by UBS
Dow Jones · 1d ago
CVS Health Cut to Neutral From Buy by UBS
Dow Jones · 1d ago
CVS Health Price Target Cut to $66.00/Share From $90.00 by Truist Securities
Dow Jones · 1d ago
Analysts Offer Insights on Healthcare Companies: CVS Health (CVS) and SurModics (SRDX)
TipRanks · 1d ago
UBS Downgrades CVS Health to Neutral, Lowers Price Target to $60
Benzinga · 1d ago
More
Webull provides a variety of real-time CVS stock news. You can receive the latest news about Cvs Health Corp through multiple platforms. This information may help you make smarter investment decisions.
About CVS
CVS Health Corporation is a health solutions company. The Company operates in four segments: Health Care Benefits, Health Services, Pharmacy & Consumer Wellness, and Corporate/Other. Its Health Care Benefits segment offer a range of traditional, voluntary and consumer-directed health insurance products and related services, including medical, pharmacy, dental and behavioral health plans, medical management capabilities, Medicare Advantage and Medicare supplement plans, and Medicaid health care management services. Its Health Services segment provides a full range of pharmacy benefit management solutions, delivers health care services in its medical clinics, virtually, and in the home, and offers provider enablement solutions. The Pharmacy & Consumer Wellness segment dispenses prescriptions in its retail pharmacies and through its infusion operations, provides ancillary pharmacy services, including pharmacy patient care programs, diagnostic testing and vaccination administration.